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Abstract 
The study of microbiota, the collective term for the microbial communities that inhabit 
us, is an increasing area of interest for the scientific community. Clostridium difficile 
infection is a prototypic case of deregulated interaction between the host and its gut 
microbiota, triggered by an environmental stimulus: antibiotics. Studies concerning the 
treatment of recurrent Clostridium difficile infection are demonstrating the ability to 
introduce different microbiota that resembles the donor’s stool through Fecal 
Microbiota Transplantation.  
Review of recent literature on gut microbiota revealed: 
1) The complex interactions between different bacterial species, the environment and 
the host play a larger than expected role in regulating the host’s metabolism and 
immune system. Understanding this relationship will most likely be useful in 
deciphering the pathophysiology of diseases with an emergent microbiota-related 
component. 
2) Healthy microbiota is probably linked to hosting a diverse set of bacteria rather than 
specific bacterial species.  
3) Diet is a predominant environmental factor, driving alterations in gut microbiota 
composition and function. Diet-induced extinctions might be unable to be recovered 
without specific intervention.  
4) Although causality has not been clearly established, altered microbiota might play a 
role in the establishment of obesity. Study of this intricate relationship may reveal new 
medical approaches. 
 
 
 
 
 
 
 
 
 
 
 
Resumo 
O estudo das comunidades de micro-organismos que habitam o ser humano constitui 
uma área de interesse crescente comunidade científica. A infecção por Clostridium 
difficile exemplifica uma interacção desregulada entre o hospedeiro e a sua flora 
intestinal, desencadeada por um estímulo ambiental: antibióticos. Publicações recentes, 
incidindo sobre o tratamento da infecção por Clostridium difficile recorrente através da 
transplantação de micro-organismos fecais demonstram a capacidade de introduzir na 
comunidade do beneficiário, micro-organismos semelhantes aos das fezes do dador.  
A revisão da literatura recente sobre a flora intestinal revelou que: 
1) As interacções entre as diferentes espécies de bactérias, o ambiente e o hospedeiro 
desempenham um papel importante na regulação do metabolismo e do sistema imune 
do hospedeiro.  
2) A composição de uma comunidade microbiana associada à saúde está associada à 
diversidade de espécies e não a espécies bacterianas específicas. 
3) A dieta é um fator ambiental predominante, levando a alterações na composição e 
função dos micro-organismos intestinais. Extinções de espécies bacterianas induzidas 
pela dieta poderão ser incapazes de ser recuperadas sem uma intervenção dirigida. 
4) A causalidade entre alterações da flora e o desenvolvimento de obesidade não está 
claramente estabelecida. No entanto, novas abordagens médicas poderão surgir através 
do estudo desta relação. 
 
 
 
 
 
 
 
 
 
 
0) Intestinal Flora Dysfunction in C. difficile infection: A successful 
microbiota-directed therapy 
What is Clostridium difficile Infection? 
Clostridium difficile is a Gram positive, anaerobic bacillus that is capable of forming 
spores and producing toxin. (1) In a susceptible host, ingestion of its spores allows the 
colonization of the large gut causing a gastrointestinal infection termed Clostridium 
difficile Infection (CDI). 
Initially termed clindamycin-associated pseudomembranous colitis (2), CDI has been 
associated with almost all classes of antibiotics. Third generation cephalosporins and 
fluoroquinolones are linked to the highest incidence of CDI(3) and even metronidazole 
can incite the disease. (4) 
Colonization is prevented by barrier properties of the fecal microbiota; weakening of 
this resistance by antibiotics is the major risk factor for this disease. Other documented 
risk factors for infection include advanced age, inflammatory bowel disease, organ 
transplantation, chemotherapy, antiacids or proton pump inhibitor use, chronic kidney 
disease, immunodeficiency, and exposure to an infant carrier or infected adult. C. 
difficile infection is associated with severe illness, infection-related mortality of 5%, and 
all-cause mortality of 15 to 20%. (5,6)  
Although antibiotics are the most frequent trigger for this infection, treatment of most 
CDI cases is based on oral antibiotic therapy. In non-recurrent infection, oral 
vancomycin or metronidazole are usually used for moderate to severe cases, with newer 
treatments such as fidaxomicin playing a more limited role due to its monetary cost. 
(5,7) 
Antibiotic treatment for an initial Clostridium difficile infection typically does not 
induce a durable response in 15 to 26% of patients. (8) A new episode of CDI within 8 
weeks after the resolution of symptoms from a previous episode, following appropriate 
treatment, defines recurrent CDI (rCDI). Both relapses and reinfections are covered in 
this broader category. (7) 
The estimated efficacy of antibiotic therapy for a first recurrence is 60%, a proportion 
that further declines in patients with multiple recurrences. (8) It is estimated that 10% 
(9) to 50% (10) of recurrent CDI cases may be attributable to reinfections rather than 
recurrence of the initial infection.  
What is Fecal Microbiota Transplantation? 
Historic perspective 
Currently, the only existing non-antibiotic treatment for recurrent CDI that is 
recommended internationally is fecal microbiota transplantation. The accepted protocol 
is described in the annex section. The earliest reference of the use of human feces as a 
medical treatment dates back to fourth century in China where it was used to treat 
patients with food poisoning or severe diarrhea. (11) The first use of fecal enemas in 
humans for the treatment of pseudomembranous colitis was reported in 1958 in a four-
patient case series. (12) Clostridium difficile as the causative agent of most 
pseudomembranous colitis was not identified until 1976. (13) A case report in which 
fecal enemas were used to successfully treat a patient with rCDI was published in 1984. 
(14,15) In the early 2000s the appearance of the BI/NAP1/027 strain of C. difficile was 
associated with widespread epidemics of CDI. This strain is characterized by high-level 
fluoroquinolone resistance, efficient sporulation, markedly high toxin production, and a 
mortality rate three times as high as that associated with less virulent strains. (5) 
Following this series of epidemics, the number of rCDI cases increased which led to the 
use of FMT in cases in which no other therapy was effective, prompting an increase of 
studies on FMT.  
Results 
The first multicenter long-term follow-up for FMT in 2012 reported a resolution rate of 
rCDI of 91% for primary cure rate (resolution of symptoms without recurrence within 
90 days of FMT) to 98% for secondary cure rate (resolution of symptoms after one 
further course of vancomycin with or without repeat FMT). No adverse effects directly 
related to the transplantation were reported. (15) The results of a randomized and 
controlled trial from 2013 for fecal microbial transplantation demonstrated that 
administration of vancomycin followed by an infusion of donor feces delivered by 
nasoduodenal tube was superior to vancomycin alone for recurrent CDI. The patients in 
the infusion group had an 81% resolution rate after first infusion contrasting with the 
31% rate in those receiving vancomycin alone. (8) 
The overall recurrence rate (defined as laboratory-confirmed reappearance of C. 
difficile and diarrhea after resolution of the previous episode) after completion of FMT 
therapy is 5.5%. Early recurrence rate of older patients is higher than that of younger 
patients, which in turn leads to reduced frequency of primary cure rates in this group. 
Most recurrences are associated with antibiotic use following infection apparently 
unrelated to the procedure. (16) The European Society of Clinical Microbiology and 
Infectious Diseases now strongly recommend the usage of fecal transplantation in 
combination with oral antibiotic treatment for multiple recurrent CDI unresponsive to 
repeated antibiotic treatment. (7) 
How FMT acts on C. difficile infection: restoration of host-microbiota interaction 
C. difficile pathogenesis begins with ingestion of its spores. They are able to resist 
stomach acids and digestive enzymes, reaching the cecum and colon unaltered. In a 
suitable host C. difficile spores then germinate into vegetative cells, leading to toxin 
production and finally disease. (17) 
Antibiotics alter bile acid metabolism 
Antibiotic exposure triggers a change in the composition of the gut microbiota which in 
turn causes a shift in the gut environment: from a medium unfavorable for C. difficile 
colonization to a medium that includes its required germinants and substrate. Out of all 
variables, bile metabolism seems to play a critical role in the development of infection.  
Analysis of the metabolic fecal products of mice treated with a 10-day course of broad 
spectrum antibiotic showed an increase in bile salts including taurocholic acid and other 
tauro-conjugated bile acids. Also, the concentration of secondary bile acids 
deoxycholate and cholate was reduced to undetectable levels. Other significant changes 
included increases in amino acids required for C. difficile germination as well as 
increases in sugar alcohols (manitol and sorbitol) and decreases in the levels of SCFAs. 
(18) Similarly, metabolic analysis of CDI patients showed high concentrations of 
primary bile acids and bile salts, while secondary bile acids were nearly undetectable. In 
contrast, post-FMT fecal samples contained mostly secondary bile acids, as did non-
CDI donor samples. (19) 
Changes in bile metabolism trigger C. difficile Infection 
Bile salts are well known germinants of C. difficile spores. The germination-specific 
receptor for taurocholic acid (a bile salt), CspC, was only recently discovered. (20) They 
serve as a signal to the spore that it has reached an anaerobic environment, the intestinal 
tract. (17) Taurocholic acid is rarely available to allow C. difficile to germinate in a 
healthy gut given the constant catabolism of bile salts by the normal flora. (21) On the 
other hand, secondary bile acids inhibit C. difficile outgrowth or germination, a function 
that has been demonstrated in both in vitro (22,23) and  in vivo (24) studies. 
The colonic flora’s role in bile metabolism 
There are a number of mechanisms by which colonic flora metabolize bile salts, 
rendering them unable to stimulate C. difficile germination: deconjugation by bile salt 
hydrolases and reduction by reductive hydroxylation reactions. Bile salt hydrolases 
catalyze the hydrolysis of amide bond in the conjugated bile salts, then form the 
deconjugated bile acids (mainly cholic and quenodeoxycholic) until free amino acids 
are dissociated. These primary bile acids may afterward undergo dehydroxylation and 
get converted into secondary bile acids (deoxycholic and lithocholic) after a series of 
changes. Bile hydrolysis is quite common for different gut bacteria and is hypothesized 
to be beneficial to commensal bacteria by liberating nutrients and conferring tolerance 
to the antimicrobial properties of bile acids. On the other hand, a more restricted group 
of bacteria have the ability to convert primary bile salts into secondary bile acids 
through 7-alpha-dehydroxylation. (21,25) 
Transplant of specific species confer resistance to C. difficile Infection 
It has been postulated that by increasing the relative abundance of members of these 
bacterial families, it is possible that FMT increases 7-dehydroxylation activity, leading 
to increased secondary bile acids and decreased primary bile acids. (19) 
Current evidence suggests that resistance to C. difficile infection might be associated to 
loss of specific bacterial features following antibiotic treatment rather than overall loss 
of gut microbiota diversity. By comparing antibiotic–treated or untreated mice in two 
independent studies, investigators found that overall community size doesn’t 
significantly differ between the two groups. (17,18) Also, high bacterial diversity was 
not necessarily associated with protection against C. difficile and low diversity was not 
necessarily associated with susceptibility to the growth of C. difficile. (17) 
To determine which group of bacteria conferred protection to infection, investigators 
then correlated loss of specific bacterial taxa with development of infection in 24 
allogeneic hematopoietic stem cell transplantation patients diagnosed with CDI out of 
which 12 were carriers without clinical infection.  
The resulting group of bacteria was then confronted with a similar group obtained from 
mice, resulting in a final group of species that correlated in both mice and human with 
resistance to infection. This group of bacteria was comprised primarily by Clostridium 
cluster XIVa, including the species with the strongest resistance correlation, 
Clostridium scindens. 
To evaluate causality they then performed adoptive transfer of the resulting consortium 
or C. scindens alone before inducing C. difficile infection. The results were a significant 
decrease in C. difficile colony-forming units as well as associated weight loss and 
mortality in both arms when compared to control. This bacterial transfer was precise 
and engraftment did not alter other aspects of microbiota structure compared to control, 
including density and biodiversity. 
The mechanism by which C. scindens, a bile acid 7-dehydroxylating bacteria, appears to 
confer resistance to infection is through conversion of stimulatory combinations of bile 
acids into inhibitory combinations of bile acids. This study showed that a fraction of the 
intestinal microbiota as precise as a single bacterial species can confer infection 
resistance to C. difficile. (17,26) 
There is a risk in manipulating bile acids directly. Increased levels of some secondary 
bile acids have been linked to gastrointestinal cancers (27) or cholesterol gallstone 
disease. (25) 
Adverse Effects of Fecal Microbiota Transplantation 
The most frequent adverse events reported after FMT were mild to moderate bloating, 
abdominal pain and diarrhea. These were short-term and subsided after a few days. (16) 
Altogether, the risks associated with FMT are few. Although the transmission of an 
undetected or unidentifiable pathogen from the donor is a possibility, there are no 
known reports of serious infectious complications resulting from fecal microbial 
transplantation that was performed with appropriate donor screening. (5) There have 
been concerns in using fecal microbiota transplantation from obese donors following a 
case-report that shows unintentional weight gain after the transplantation. (28) It is 
important to note that some recipients of FMT developed new immune conditions in 
some studies, such as rheumatoid arthritis, peripheral neuropathy, Sjögren’s syndrome, 
and idiopathic thrombocytopenic purpura. It is not known if they were related to the 
FMT. (11) Disease flares in patients with a history of IBD treated for CDI have been 
reported in the literature. A case report published in 2013 presented a case of a patient 
treated with FMT for recurrent CDI which resulted in a flare of a long time quiescent 
ulcerative colitis soon after the treatment. Although there is a noteworthy amount of 
patients treated for IBD with a FMT, it is important to expect unforeseeable 
consequences in this population. There are risks associated with the procedure to 
administer the FMT by colonoscopy, sigmoidoscopy, or the upper route when aspiration 
could occur. Deaths have occurred as a direct result of FMT. A case of toxic megacolon 
and septic shock following the procedure was reported. Two report cases of fatal 
aspiration pneumonia have also been reported, both of which happened in patients 
sedated for the procedure, upper endoscopy and colonoscopy.(29,30) 
Changes in microbiota following FMT 
The dysbiotic state found in rCDI patients is characterized by a large expansion of 
Proteobacteria (primarily members of the order Enterobacteriales, which contains the 
family Enterobacteriaceae), and FMT is associated with reemergence of dominance by 
members of the Bacteroidetes and Firmicutes phyla. 
Immediately after FMT, there is a rapid normalization of bacterial fecal sample 
composition from a markedly dysbiotic state to one representative of normal fecal 
microbiota. (31) Healthy bacterial interaction networks which were absent beforehand 
can be detected immediately after the transplant, testifying the community-level 
changes that occur. The changes in microbiota adopt donor-specific signatures that are 
maintained over time. (32) 
The first characterization of long-term microbiota changes in patients after FMT was 
performed by Song et al. Samples from fourteen pairs of healthy donors and rCDI 
patients treated successfully by FMT were collected up to one year after the 
transplantation. These authors argued that, although there was a disappearance of 
diarrheal symptoms immediately after FMT, as changes in Firmicutes continued to 
occur, full microbiota recovery from rCDI might take much longer than expected.(33) 
On the other hand, a more recent study highlighted that the drifts in microbiota 
composition observed following FMT fall under the normal microbial variation of 
healthy adults. By comparing donor and recipient sample composition and variability 
they found that these are characterized by highly dynamic shifts that nonetheless remain 
within the compositional range of normal fecal microbiota. This observation is 
consistent with known rapid responsiveness of the fecal microbiome to environmental 
inputs, such as dietary variations, and drifts in microbiota composition over time in 
healthy individuals. The dynamic nature of intestinal microbiota is an intrinsic property, 
which should be taken into account when considering how therapeutic interventions, 
including FMT, impact its composition over time. (31) 
Further considerations:  
After establishing the efficacy of FMT, the emphasis of current research is now directed 
towards the standardization of the technique, assuring its safety and finding new 
indications.  
Patient-donor relationship: There isn’t a significant difference in cure rate or recurrence 
rate between patients treated with patient-related donors or unrelated healthy donors. 
(16) 
Fresh vs. Frozen stools: The viability of fresh stools is limited, being usually estimated 
at up to 6 hours. (34) A double-blind randomized clinical trial from 2016 to determine 
whether frozen FMT administered through enema is non-inferior to fresh FMT for 
patients with recurrent or refractory CDI concluded that frozen FMT did not result in a 
worse proportion of clinical resolution of diarrhea. (35) The use of frozen FMT 
ameliorates the risk of transmitting pathogens from the donor to the recipient as it 
allows for the proper screening of the sample before the procedure. It also permits the 
use of FMT in non-specialized centers without the required technical facilities for 
sample screening.  
Route of Administration: Although no random controlled study has established any 
route of administration as preferred, a meta-analysis from 2015 found that the primary 
cure rate of the lower gastrointestinal route group was significantly higher than that of 
upper route (81% vs. 93%). (16) Even so, a small randomized, controlled pilot study 
from 2014 using frozen inoculum concluded that nasogastric tube administration 
appeared to be as effective as colonoscopic administration. (36) In another study, using 
oral administrated capsules containing frozen FMT from unrelated donors achieved a 
resolution rate of diarrhea of 70% after primary treatment and greater than 90% with 
subsequent treatments. (34) This result matched a smaller study’s result of cumulative 
clinical cure rate of 89% for orally administered capsules. (37) Using capsules as a form 
of administration might prove useful in critical patients unable to undergo more 
invasive techniques.  
Cost-effectiveness: A cost-effective analysis on colonoscopic administration of FMT 
compared with vancomycin evaluating the use of FMT at the third recurrence of CD 
diarrhea found the first to be the most cost-effective treatment strategy. (38)  
Non-recurrent CDI: It has been suggested that FMT might have a prospective role in the 
treatment of non-recurrent CDI. In a series of cases, 14 subjects with severe non-
recurrent CDI refractory to medical treatment of vancomycin and metronidazol obtained 
a cure rate of 79% after intestinal microbiota transplant. More studies are required to 
clarify this indication. (39) 
Bacteriotherapy: The unappealing FMT might be soon replaced by bacteriotherapy, a 
more specific, controllable, and possibly effective treatment. Bacteriotherapy is not a 
new concept. In 1989 a series of 5 patients was treated for rCDI by rectal infusion of a 
bacterial mixture which resulted in the prompt loss of C. difficile and its toxin from the 
stools of all patients following treatment. (40) 
An upcoming study “RePOOPulating the Gut” has established proof of concept for this 
principle. The authors developed a synthetic stool mixture by culturing a stool sample 
obtained from a healthy donor and collecting bacterial isolates. The stool substitute 
consisted in a preparation of 33 different intestinal bacteria. It was administered to two 
patients with rCDI and a clinical cure was achieved. The patients remained symptom 
free at 6 months of follow-up even after several courses of treatment with antibiotics for 
unrelated infections. Advantages of a synthetic stool mixture are that the composition of 
the administered bacteria is known and can be controlled, the procedure is reproducible 
and other pathogens such as viruses, fungi and archaea can be excluded from the 
mixture. (1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1) The Importance of Gut Microbiota 
All of the surfaces of the human body that are exposed to the environment are colonized 
by microbes. Although only 20-60% of the microbes identified in different body sites 
have been cultured, recent technological advances such as 16S ribosomal RNA gene 
sequencing or whole-genome shotgun have allowed the characterization of microbial 
entire genomes and metabolic pathways directly from their natural source.  
These advances have spiked the interest of the scientific community in studying the 
human microbiome. The microbiome is defined by a fluctuating collection of genes and 
gene products which is susceptible to alteration from environmental perturbations, such 
as antibiotic treatment and infection. Yeasts, archaea and viruses also form part of the 
human microbiome but most published studies have focused on host-associated 
bacterial communities. (41–43) 
Initiatives such as the Human Microbiome Project (44) or the Metagenomics of the 
Human Intestinal Tract (45) try to establish a database for the normal human 
microbiome by analyzing hundreds of healthy donors.  
Among body sites, the highest numbers of taxonomic units and genetic contents have 
been observed in stool samples. (45) The focus on the study of the human gut 
microbiome is supported by the fact that gut microbiota compose around 70% of the 
total microbiota found of the human body.  
Composition of Gut Microbiota 
The majority of human-associated bacteria fall within four phyla: the very prevalent 
Firmicutes, and Bacteroidetes and the least prevalent Actinobacteria and Proteobacteria. 
Each phylum contains many different bacterial species. (41) The Firmicutes phylum is 
composed of gram-positive, anaerobic, spore-forming bacteria that ferment simple 
sugars to produce a variety of SCFAs. Within Firmicutes, members from the 
Lachnospiraceae and Ruminococcaceae family make up 50 to 70 percent of the colonic 
bacterial population. Bacteroidetes are gram-negative, anaerobic, nonspore-forming 
bacteria that are enriched with enzymes to degrade carbohydrates. (46) 
Curiously, even the more abundant species in healthy individuals such as 
Faecalibacterium prausnitzii, Roseburia intestinalis, and Bacteroides uniformis can 
present at <0.5% relative abundance in some healthy individuals. (47) 
We share a core functional microbiome but not a core group of microbiota. Core 
functions of the gut include carbohydrate and amino acid metabolism, and these can be 
performed by several species of microorganisms. Some functions aren’t a part of the 
core: pathogenicity islands, vitamin and drug catabolism, motility and nutrient 
transporters are pathways that vary between individuals. (47) 
Functions of the Gut Microbiota 
There is a complex symbiotic relationship between gut microbiota and its host. The 
microbiota carries out specific functions unable to be performed by the host.  
Production of Short Chain Fatty Acids 
Bacteria play an important functional role by metabolizing the undigested 
carbohydrates, lipids and protein that reach the colon each day. They ferment complex 
indigestible carbohydrates and amino acids into short chain fatty acids (SCFAs), 
(acetate, butyrate, propionate and valerate). Members of the Firmicutes and 
Bacteroidetes account for most of the SCFA production with Firmicutes being the 
dominant producers of butyrate. (48) 
While butyrate is used as an energy substrate for the colonic epithelium and can 
strengthen the colonic defense barrier by inducing secretion of protective factors and 
acidifying the colon lumen (49) (e.g. mucin, trefoil factors or antimicrobial peptides) 
(50,51) acetate and propionate are carried into the bloodstream and become available as 
energy substrate for peripheral tissues. (52) It is estimated that SCFA represent 5-10% 
of the host’s daily energy intake. (53) 
SCFAs play a vast number of roles regulating host homeostasis. They inhibit gut 
motility through stimulation of peptide YY production, allowing gut microbes to digest 
more polysaccharides. (54) They are involved in appetite control by interacting with 
hormone secreting gut endocrine cells (49) and may also play a role in leptin production 
by adipocytes. (55) Also, SCFAs play an important role in the suppression of the 
inflammatory response: butyrate, and proprionate actively promote the generation of 
Foxp3+ regulatory T (Treg). (51) 
Butyrate in special takes part in immune modulation, cell cycle inhibition, induction of 
programmed cell death and cellular differentiation in a variety of cell types. Recently it 
has also been shown that butyrate is able to alter dendritic cell response to bacterial 
antigens, up-regulating IL-23 production. (51) 
Lipid Metabolism 
The intestinal flora also performs a fundamental role in lipid metabolism, specifically 
the metabolism of biliary acids, as described previously. Other than acting on the 
metabolism of fat and cholesterol, biliary acids are also able to modulated lipoprotein, 
glucose, drug and energy metabolism by binding to the bile-acid-synthesis controlling 
nuclear receptor farnesoid X receptor and the GPCR TGR5. (52)  
Other metabolites 
Besides SCFAs gut microbiota also influences other important metabolites. Through 
modulation of the metabolism of tryptophan, a precursor of serotonin production, gut 
microbiota is able to influence behaviors and pathology that rely on serotonergic 
neurotransmission. (56) Recent research is now focusing on the gut-brain axis (57) to 
expand on host-microbiota interaction. Various B-vitamins and folate are 
biosynthesized by gut microbiota.(58) 
Pharmabiotics 
The gut microbiota is also relevant regarding drug metabolism. More than 30 drugs that 
made it onto the market have been identified as substrates for colonic bacteria. (59) The 
importance of microbiota metabolism of a pharmaceutical product cannot be overstated. 
In 1993 in Japan sorivudine, drug acting on herpes zoster infection, was introduced into 
the market. It was later discovered to be transformed by the gut microbiota into an 
inhibitor of 5-fluorouracil leading to toxic levels of this drug. Within forty days this 
interaction was responsible for the death of eighteen patients with cancer and herpes 
zoster leading to the withdrawal of sorivudine from the market. (60) 
Microbiota and Immunity 
Much of our current knowledge on the interactions between the microbiome and the 
immune system comes from studies on germ-free animals. These can be used in their 
sterile condition or they can be colonized by a single known species or consortium, 
originating gnotobiotic animals (from the greek: known life). (61) 
The immune system modulates microbiota 
Every day the intestine is exposed to an enormous microbial load. An important 
function of the immune system of the gut is to control and limit this exposure.  
By stratifying the microorganisms into layers, the mucous produced by the gut limits 
the contact with the intestinal lining. In the colon, mucous exists in two different layers, 
an external microbial-rich layer and an internal less colonized layer. This separation is 
not only dependent of structural differences between layers but also dependent of 
secretion of specific IgA produced by lamina-propria B-cells as well as antimicrobial 
peptides, produced by the epithelial cells, namely RegIIIγ (61) 
The uptake of antigen and microbes from the lumen of the gut and its delivery to 
underlying lymphoid tissue is performed by specialized epithelial cells, the M cells, 
present in Peyer’s patches. Bacteria that penetrate the intestinal barrier are engulfed by 
dendritic cells residing in the lamina propria and are carried alive to the mesenteric 
lymph nodes. However, these bacteria do not penetrate to systemic secondary lymphoid 
tissues. In this manner, there is an anatomical mechanism that limits the interaction of 
the microbiome with the systemic immune system. Limiting the innate response enables 
an increased systemic response by the host organism: Mice unable to produce IgA have 
an IgG response against the commensal flora. Mice with a limited TLR-response also 
produce IgG against commensal microorganisms.(61) 
Defects in the immune system impact the microbiota in a manner that predisposes to 
disease. In several studies, microbiota obtained from genetically immune-compromised 
mice was notably altered which conditioned the development of pathology. After 
transferring it to wild-type mice, the associated diseased phenotype was transmissible. 
(61) 
Host secretions not only limit the microbial load but can also change its composition, 
either by providing an ecological niche for specific bacteria or by selecting against 
specific bacteria. Mucin, a glycosylated protein covering the intestinal epithelium, is a 
specific growth substrate for many commensal gut microbes. (62) 
Other host mechanisms relevant for microbiota modulation include intestinal motility 
and other secretions, such as Paneth cell secreted defensins, gastric acid or, the 
previously discussed biliary acids. 
Microbiota modulates the host immune response 
In the same way that the immune system modulates the gut microbiota, gut microbiota 
is known to modulate the development and homeostasis of the immune system. The 
development of various immune-related cells is influenced by gut microbiota. The gut 
mucosal immune system is the largest lymphoid site in body, and gut bacteria interact 
with lymphoid follicles of the gut mucosa, and regulatory and effector T cells. 
Dysbiosis, that is, disease-associated microbiota, changes the immune regulatory 
systems that normally manage inflammation in the gut, and is associated with immune-
mediated disorders. (63) 
Germ-free mice have no commensal intestinal microbiota and as such exhibit an 
underdeveloped immune system: reduced secretory IgA, defects in development of gut-
associated lymphoid tissues, smaller Peyer’s patches and mesenteric nodes. Also, an 
unorganized myenteric plexus and reduced intestinal motility. These changes translate 
in an increased susceptibility to infection in these animals. However, reintroduction of 
intestinal flora in GF animals can restore the proper organization of the intestinal 
immune system. (57) 
Beyond its role on the development of the immune system, the gut microbiota is able to 
actively change the immune response of its host. Much of what is known about 
microbiome–host immune interactions has been achieved from the study of single 
bacterial members: (64) 
 Colonization of gnotobiotic mice with a consortium of mouse Clostridial strains, 
results in the expansion of lamina propria and systemic Tregs. (65) 
 Bacteroides fragilis, a commensal bacterium produces polysaccharide-A which 
induces an IL-10 response in intestinal T cells which prevents the expansion of 
Th17 cells, actively inducing immunitary tolerance.(66) 
 Colonization of mice with segmented filamentous bacteria (SFB) results in 
accumulation of Th17 cells in the lamina propria. This allows the adherence of 
SFB to the colonic mucosa and, by enhancing the immune response confers 
resistance to pathogen colonization.(67) 
In all three of these examples, bacteria are able to enact a systemic influence on the 
host’s immunity.  
There is also increasing evidence on the role of the microbiome in the establishment of 
auto-immune diseases.  
 In germ-free mice models of Th17 cell-dependent arthritis, mono-association 
with SFB is sufficient to induce disease. A single commensal microbe, via its 
ability to promote a specific Th cell subset, can drive an autoimmune disease. 
(68) 
 In non-obese, diabetic mice (NOD), models for type 1 diabetes (T1D) in 
humans, the incidence of T1D is dependent on immune-microbial interaction. 
Specific pathogen-free NOD mice with a genetic disruption of TLR signaling do 
not develop T1D. This effect is dependent on commensal microbes because 
genetically identical but germ-free mice develop robust diabetes, whereas 
colonization of these germ-free mice with a defined microbial consortium 
attenuates T1D. (69) 
Studies like these provide increasing evidence that the interaction of gut microbiota 
with the innate immune system might be a vital factor modifying human disease.  
Bacteria-bacteria interaction 
Beyond host-microbiota interaction, bacteria can also interact with one another. Quorum 
sensing is a cell-cell communication mechanism through which bacteria count their own 
numbers by producing and detecting the accumulation of a signaling molecule that they 
export into their environment. (70) Bacteria use quorum sensing communication circuits 
to regulate a diverse array of physiological activities. These processes include 
symbiosis, virulence, competence, conjugation, antibiotic production, motility, 
sporulation, and biofilm formation. (71) Communication also includes the movement of 
genes between bacterial species and strains. Gene transfer can happen so that virulence 
genes are transferred from pathogens to commensals, and these may also serve as 
reservoirs of genes that encode antibiotic resistance. (43) 
Stable state 
Gut microbiota normally exists in a stable state. This stable state can tolerate a certain 
amount of perturbation before it changes towards a different equilibrium state. 
Exogenous factors, such as antibiotics, invasive species or diet, impact the microbiota of 
the host. For instance, by exposing healthy volunteers to two courses of ciprofloxaxin 
over a 10-month period, the fecal microbiota reached a stable state similar to but yet 
distinct from the pre-treatment state. (72) In the same manner, three individuals with 
dyspepsia given one week of metronidazole, clarithromycin, and omeprazole had a state 
shift that persisted up to four years without additional antibiotic treatment. (73) In both 
cases, significant increases in antibiotic-resistance genes persisted for years.  
Colonization Resistance 
The stability of the gut microbiota is guaranteed by another fundamental role of the 
microbiota, colonization resistance. It translates the ability of native microbiota to 
prevent the establishment of harmful or potentially beneficial microbes, by competing 
for attachment sites and nutrients, and through production and secretion of antimicrobial 
products. (47,51) 
Most studies involving probiotics use a single species or a few species thought to be 
beneficial. However, probiotic challenges typically do not introduce lasting changes in 
the host microflora. (74) 
In rat models, transplanting exogenous microbiota resulted in a marked increase in the 
microbial diversity of the recipients. However, when transplantation was performed 
after antibiotic intake, an increase in the establishment of donor phylotypes was not 
observed. (75) This study challenges the more intuitive view that the native community 
is more resilient to colonization than a less diverse post-antibiotic community. An 
indigenous gut microbial community might be reshaped to an extent not previously 
anticipated. 
In summary, resilience is a characteristic of healthy microbiota but being resilience 
doesn’t characterize a microbial community as healthy. (47) 
Establishment of Adult Microbiota 
Although the intrauterine environment is generally considered sterile, recent evidence 
showed a unique placental microbiota composed of nonpathogenic commensal 
microbiota. (76) The earliest infant stool sample, the meconium, is free of detectable 
viral particles and harbors very low diversity of bacteria. Babies are exposed to 
microbes from different environments immediately upon birth and are rapidly colonized 
by the microbes they first encounter, either from their mother’s vagina in eutocic 
delivery or from skin microbes in caesarian-section births. Delivery mode has been 
hypothesized to influence immunological functions during the first year of life via gut 
microbiota development, with babies delivered by caesarean section having lower 
bacterial cell counts in fecal samples and a higher number of antibody-secreting cells. 
(41) Although biological mothers are in a unique position to transmit an initial inoculum 
of microbes to their infants during and following birth, an analysis of mothers of 
teenage USA twins showed that their fecal microbiota were no more similar to their 
children than were those of biological fathers. Furthermore, monozygotic and dizygotic 
adult twins share equally similar microbiota. Shared environment rather than genes 
might drive familial similarities, for example, differences in the microbiota and the 
microbiome may help explain interpersonal variations in gut metabolic processes, 
including metabolism of drugs and dietary substrate responses. (77) 
Besides providing ideal nutrition, breast milk is dense in human milk oligosaccharides 
and other bioactive molecules that nurture the proliferation of a protective gut bacterial 
community enriched in bifidobacteria. (78) It has been proposed that suckling might 
provide vertical mother-infant transfer of microbes not only of skin associated bacteria 
(through direct contact) but also, through a hypothesized entero-mammary pathway, in 
which viable maternal gut bacteria reach breast milk. (79) 
The diversity of both bacteria and viruses in the infant gut is initially very low, and then 
climbs through early development. Early colonizers are generally aero-tolerant, as the 
gut initially contains oxygen, and then are replaced by anaerobes that are typical of the 
adult gut microbiota. The progressive shifts in community composition seen in 
microbiota development are related to changes in its functional profile. The earliest 
microbiome is enriched in genes facilitating lactate utilization and functional genes 
involved in plant polysaccharide metabolism are present before the introduction of solid 
food, preparing the host for dietary change. (41) Phylogenetic diversity increases 
gradually over time evolving towards an adult-like configuration within the 3-year 
period following birth. (77) Once the microbiota has reached maturity it remains mostly 
stable until old age. (41) Adult individuals studied over a long period of time registered 
a high level of variability in both diversity and community structure, signifying that a 
mature and stable microbiome does not correspond to a static microbiome. (80) The 
microbiota composition in the elderly is different from that of young adults. Variability 
in community composition is greater in this age group than for adults, which could be 
related to the greater range of morbidities associated with age and the subsequent use of 
medications to treat them. (41) 
Early life is critical for microbiota development 
A landmark study on microbial development in mice found that disrupting the 
microbiota during a critical, early-life, time window resulted in long-term metabolic and 
immunity changes. Cox and colleagues studied the exposure of mice to low dose 
penicillin during a specific time window around birth, that is, mother exposure and 
subsequent weaning period. They found that transient changes to the microbiota had a 
sex-specific, long-term effect on body composition. These changes included increased 
total mass, fat mass, increased hepatic expression of genes involved in adipogenesis as 
well as others. The metabolic changes evidenced were not caused by direct effects of 
antibiotics but rather by derived changes in the gut microbiota. (81) In a different study, 
germ-free mice accumulate invariant natural killer T cells in the colonic lamina propria 
and lung, increasing morbidity in models of IBD and allergic asthma.  Colonization of 
neonatal-but not adult-GF mice with a conventional microbiota protected the animals, 
indicating that early childhood is a critical time window for contact with microbiota. 
(82) 
Both of these studies suggest a strong role of the microbiota in establishing long-term 
effects on immunity and metabolism during infancy. In a recent study reflecting this 
concern, investigators were able to partially restore microbiota of cesarean-born infants 
via vaginal microbial transfer immediately after birth. Although a follow-up 
longitudinal study is necessary, the objective of the study to establish proof of principle 
for this technique was a success. (83) 
2) Eubiosis and Dysbiosis 
A healthy microbiota is defined by high diversity and an ability to resist change under 
physiological stress. In contrast, microbiota associated with disease, dysbiosis, is 
defined by lower species diversity, fewer beneficial microbes and/or the presence of 
commensals that have the potential to cause harm (pathobionts). (84)  
Shifts in microbial community composition can destroy the mutualistic relationship 
between host and microbiota, compromising human health status. Intestinal dysbiosis 
has been linked with important human diseases, including autoimmune and/or 
inflammatory disorders, such as IBD, metabolic disorders, such as, obesity, type 2 
diabetes, as well as allergies, and neurological disorders. (51) 
In genetically susceptible hosts, the changes in the gut microbiota composition could 
have a profound impact on chronic disease development. For example, a study by Eun 
et al was able to trigger colonic inflammation in all germ-free, IL10 deficient mice 
belonging to two distinct strains after colonization with an IBD-associated bacterial 
consortium. (85) 
In the case of gut ecology, the immense number of species and strains and the complex 
relationships between them, the environment and the host make it difficult to ascertain 
if a specific pathogen is associated with a specific disease, that is, Koch’s postulate. (84) 
Although no single species acts as a biomarker of dysbiosis, some consistent alterations 
in specific disease states have been described such as Faecalibacterium prausnitzii in 
IBD (86) or Akkermansia muciniphila in DM2 (87). 
The associations described for these species are not in any chance ubiquitous. In the 
case of both these species, a recent review highlighted several studies depicting 
contradictory or even mutually exclusive associations. The authors suggested that 
strains of F. prausnitzii, that have distinct metabolic impacts in the gut system, were 
inseparable by current rRNA-based classification. (62) 
The Human Microbiome Project has shown that despite significant taxonomic variation, 
there is a similarity in the functional profile of the microbiome of healthy individuals. 
(44) As such, instead of key bacterial taxa, identifying specific microbial gene or 
metabolic markers associated with health and disease might serve as potential 
diagnostic markers. For instance, reduction of Rumicoccaceae and Lachnospiraceae 
family microbiota, SCFA producers, in CDI can be interpreted as depletion in butyrate-
producing bacteria. (33,88) Also, Roseburia intestinalis has been shown to have 
negative correlations with subcutaneous adiposity, body weight, liver weight, serum 
insulin, FGF21 levels, and inflammation markers in mice as well as similar alterations 
in humans, probably due to its role as a butyrate producer. (89) 
Diversity as a Marker of Eubiosis 
Microbial diversity seems to be a good a marker of eubiosis as gut communities of 
lower diversity are often associated with disease phenotypes in humans. (90) 
Body sites with restricted microbial diversity in the healthy state such as the esophagus 
and the vagina might not tolerate increased microbial diversity without adverse 
consequence, for instance in triggering the development of bacterial vaginosis and 
chronic esophageal inflammation and cancer. (43) Several publications describe the 
differences between the microbial composition of humans from developed countries and 
cohorts representing nonmodern societies. A common finding in all these studies is the 
lowered bacterial diversity in the developed country group. (91) 
For example, differences were found between the composition and gene function 
between the least diverse USA microbiome and the more diverse Malawian/Amerindian 
microbiomes.(77) The authors proposed that the western lifestyle (diet) affected the 
bacterial component of the gut microbiota by obviating the need for a wide diversity of 
microorganisms needed to utilize the many fibers and other nutrients of a more plant-
nutrient rich diet. 
The mechanisms that link microbiota diversity and health are still unknown, but SCFAs 
appear to be one likely mediator. A modern diet is poor in microbiota-accessible 
carbohydrates (MACs) and as such it is poor on beneficial microbial metabolites. The 
term MAC was proposed by Sonnenburg and Sonnenburg (91) allows a better definition 
for carbohydrates destined to microbial fermentation. Terms such as fiber that 
encompass bulking, non-fermenting agents or plant polysaccharides that dismiss 
nonplant carbohydrates should be used sparingly. A diet low in exogenous MACs 
induces reduced microbial diversity by selecting a group of species that are more apt in 
using host-derived MACs, such as mucin glycans.  
 
 
 
 
 
3) Diet shapes the microbiota 
Diet shapes the microbiota in mice 
In order to establish the relative importance of diet in shaping the gut microbiota, 
investigators fed five inbred strains of mice deficient for genes relevant for host-
microbiota interaction as well as a group of outbred mice a HF/HS diet. In all groups 
there was a consistent change in microbial community that was characteristically rapid, 
reproducible, and reversible. This study illustrates the importance of diet when 
compared to genetic associations in shaping the gut microbiota. (92)  
Ridaura et al studied germ-free mice colonized with flora from obesity-discordant 
human twins. Their study found that adiposity is transmissible from human to mouse 
subjects, that is, transplantation of the human obese twin transmitted the obese 
phenotype to the mice. Also, they showed that, by cohousing the two groups of 
(coprophagic) mice, that is, the mice transplanted with the lean twin’s microbiota (Ln) 
and the mice transplanted with the obese twin’s microbiota (Ob), that the latter resisted 
the development of obesity. This phenotype rescue correlated with the invasion of 
Bacteroidales species originating in the Ln mice and was only evident in mice fed a diet 
lower in saturated fats and high in food and vegetables. These results reveal that 
transmissible and modifiable interactions between diet and microbiota influence host 
biology. (93)  
Another murine study highlights the reasoning that in some genetic backgrounds, 
environmental reshaping of the microbiota can significantly improve the development 
of metabolic syndrome features while in others, host-related factors might be dominant. 
The same mouse strain, originating from different vendors was compared. The 129T 
strain from Taconic Farms is usually susceptible to developing diet-induced obesity and 
the 129J from Jackson laboratories is resistant to the development of metabolic 
syndrome. When these two groups of genetically identical mice are co-housed and fed 
the same diet (environmental normalization), the 129T becomes metabolic syndrome 
resistant after 3 generations. On the other hand, a different strain of metabolic syndrome 
prone B6J mice housed under the same conditions acquired similar microbiota but did 
not change its phenotype. (89) 
Diet shapes the microbiota in humans 
A controlled-feeding study of 10 subjects showed that microbiome composition 
changed detectably within 24 hours of initiating a high-fat/low-fiber or low-fat/high-
fiber diet, but that its overall microbial identity (enterotype) remained stable during the 
10-day study. Thus, alternative enterotypes might be associated with long-term diet. 
(94) Long-term dietary interventions may allow modulation of an individual's 
enterotype to improve health. 
Consumption of diets composed entirely of animal or plant products alters microbial 
community structure in just a few days. The animal-based diet increased the abundance 
of bile-tolerant microorganisms and decreased the levels of Firmicutes that metabolize 
dietary plant polysaccharides, reflecting trade-offs between carbohydrate and protein 
fermentation. Finally, increases in the abundance and activity of Bilophila wadsworthia 
on the animal-based diet support a link between dietary fat, bile acids, and the 
outgrowth of microorganisms capable of triggering inflammatory bowel disease. (95) 
Dietary intervention in a group of 49 overweight or obese individuals resulted in loss of 
fat mass and was accompanied by improvements in clinical markers such as lipid and 
insulin values, insulin resistance, and measures of inflammation for both the LGC and 
HGC groups. The LGC cohort also registered an increase in gene richness that 
approached but still remained significantly lower than the HGC. However this 
improvement was less efficient for inflammation variables in individuals with lower 
gene richness. Low gene richness may therefore have predictive potential for the 
efficacy of dietary intervention. (96) 
Another study comparing elite athletes to normal weight and overweight/obese 
individuals found that, microbiota diversity indices positively correlated with protein 
intake and creatine kinase suggesting that diet and exercise are drivers of biodiversity in 
the gut. The protein and microbiota diversity relationship was further supported by a 
positive correlation between urea levels, a by-product of diets that are rich in protein, 
and microbiota diversity. (97) 
In humans the available evidence would suggest that the differences in the gut 
microbiota are associated with obesity probably result from the utilization of a high-
calorie, high-fat and high-carbohydrate Western diet. (98) The composition of the 
human gut microbiota is rather stable and short-term dietary interventions do not 
profoundly change the microbiota composition. Nonetheless, the microbial gene 
expression and therefore the functional profiles seem to adapt to changes in diet rapidly. 
(99)  
The knowledge of the mechanisms by which changes in the microbiome occur allows us 
to foresee changes induced by exogenous sources. Changes in diet are the seemingly 
most accessible manner of manipulating the microbiota in order to improve human 
health and to treat or prevent disease. 
Diet, microbiota and drugs 
Diet induced changes may also play a role in pharmacokinetic pathways. Eggerthella 
lenta is a gut colonizing Actinobacterium that can transform digoxin into the inactive 
metabolite, dihydrodigoxin. By expanding on the knowledge that arginine inhibits this 
reaction in vitro, investigators found that by increasing the dietary protein in germ-free 
mice colonized with E. lenta the serum and urine digoxin concentration significantly 
increased. Identification of gut microbial biomarkers through rapid qPCR-based as well 
as dietary adjustments could be able to guide dosage schemes. (100) 
Possible limitations to dietary efforts: Long-term effects of dietary changes in 
human populations 
The changes of the microbial membership of calcified microbial dental plaque in 
European skeletons allowed the identification of periods in history corresponding to the 
largest shifts in the oral microbial community. The transition from hunter-gatherer to 
farming shifted the oral microbial community to a disease-associated configuration. The 
composition of oral microbiota remained unexpectedly constant between neolithic and 
medieval times, after which (the now ubiquitous) cariogenic bacteria became dominant, 
apparently during the Industrial Revolution. Modern oral microbial ecosystems are 
markedly less diverse than historic populations, which might be contributing to chronic 
oral (and other) disease in postindustrial lifestyles. These two periods correspond to the 
greatest dietary shifts in human evolution. (101) 
To test the hypothesis that a diet low on microbiota-accessible carbohydrates causes a 
decrease in microbiota diversity, mice colonized with human microbiota were switched 
from a high-MAC diet to a low-MAC diet for 7 weeks. A significant reduction in 
diversity was noted. By switching back to a high-MAC diet, there was a partial recovery 
of diversity markers. The low-MAC diet perturbation induced permanent loss of 
diversity on the microbiota. The investigators then bred both the control group and the 
test group to understand if this effect was magnified over generations. Every generation, 
the descendants were weaned onto the respective diet of their parents. After reproducing 
the new parents were then switched to a high-MAC diet. With each new generation the 
low-MAC diet resulted in a progressive loss of diversity that was progressively less 
recoverable with introduction of a high-MAC diet. This model suggests that over 
several generations there were increasing, irreversible extinctions of microbial species 
due to a low abundance of MAC in the diet.  By the fourth generation, mice in the test 
group were transplanted (through gavage) with fecal samples from fourth generation 
controls. This resulted in the reestablishment of bacterial diversity. (102) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4) The impact of Gut Microbiota on a common “western” disease: Obesity 
The western diet and lifestyle is associated with loss of gut microbial diversity and the 
appearance of western diseases the most frequent of which is obesity. Over the 
following pages the main evidence proving this association will be exposed. 
Gut microbiota is altered in obesity 
Several changes have been reported in regards to the microbiome in overweight and 
obese individuals. These changes are probably not a mere consequence of obesity. In 
mice, the obese phenotype can be transmitted by gut microbiota transplantation, 
indicating that gut microbial populations may have an active role in the development of 
obesity. (103) A number of studies have demonstrated gut composition differences 
between obese and lean human subjects. The most reported alteration is a reduction in 
the Bacteroidetes:Firmicutes proportion. A meta-analysis reviewing these results found 
that the only reproducible and significant alteration at the phylum level is a decrease in 
the absolute number of sequences of Firmicutes in the obese subject’s group. At a genus 
levels there was significantly depletion in Bifidobacteria, which are members of the 
Actinobacteria phylum. (104)  
Microbial diversity in obesity 
The importance of microbial diversity has been identified as an important factor related 
to obesity. When tested for bacterial richness, a group of 292 individuals split into two 
groups; one consisting of a low-gene-count and a high-gene-count group representing 
lower and higher microbial diversity respectively. The LGC group included a 
significantly higher proportion of obese participants and was characterized by more 
marked adiposity associated with increased serum leptin, decreased serum adiponectin, 
insulin resistance, hyperinsulinemia, increased levels of triglycerides and free fatty 
acids, decreased HDL-cholesterol and a more marked inflammatory phenotype.  
The investigators found that the changes in the metabolic profile of the LGC group 
suggested that this group harbors an inflammation-associated microbiota. These 
changes included: a) a reduction of butyrate-producing bacteria; b) increased mucus 
degradation potential c) reduced hydrogen and methane production potential combined 
with increased hydrogen sulphide formation potential; d) an increase in 
Campylobacter/Shigella abundance; and e) an increased potential to manage oxidative 
stress. (90) 
Mechanisms linking microbiota and obesity 
Early research suggested that the increase in body weight associated with gut microbiota 
was due to an increased capacity of the microbiota to extract nutrients from the diet as 
well as induced changes in the metabolism of the host (e.g. increased fatty acid 
oxidation and triglyceride storage in the liver). (105,106) 
These studies were performed by comparing the difference in weight gain between 
germ-free mice and conventionally raised mice groups. However, another study (107) 
found no significant difference in weight gain between GF and CONV groups under 
low fat diet, reporting no linkage between gut microbiota and diet-induced obesity.  
Although these statements might represent a conflicting image, when critically 
interpreted we find important confounding factors. Dietary formulations presenting a 
similar macronutrient balance but different sources of carbohydrates and fat, as well as 
differences in mice strains are prevalent across GF and CONV mice comparison studies. 
(62) 
Overall, GF-CONV comparisons do find differences in energy metabolism between the 
two groups. These differences, although not ubiquitous, link microbial presence to 
obesity. (62) 
Suppression of Fiaf as a probable mechanism 
The first studies to explore the causal mechanism between this association proposed that 
the microbial colonization of the gut introduced more calories through processing of 
dietary polysaccharides and that suppressed Fiaf (Fasting induced adipocyte factor) 
activity in the gut epithelium led to increased LPL activity in adipocytes, promoting TG 
storage of calories harvested from the diet. (106,108) More recently, the paradigm 
shifted and inflammation is thought to be the most relevant mechanism regarding this 
association.  
The role of gut inflammation and diet 
Obesity and associated metabolic disorders are characterized by chronic or low-grade 
inflammation. (109) Bacterial lipopolysaccharide (LPS), a breakdown product of the 
outer membrane of Gram-negative staining bacteria, has been proposed as a triggering 
factor for the increased inflammatory process in obese individuals and diet seems to 
play an important role in starting that process. Mice fed with a high-fat diet demonstrate 
augmented plasma LPS at a concentration sufficient to increase body weight, fasted 
glycemia, and inflammation. Accordingly, LPS infusion in normal diet-fed mice raised 
a metabolic response similarly to high-fat feeding. The described metabolic 
endotoxemia was characterized as a 2 to 3-fold increase in serum LPS. This increase 
was still 10–50 times lower than values that could be reached during sepsis or other 
infections. (110) Changes in inflammation include an increase in intestinal permeability, 
plasma LPS, as well as increased phosphorylation of myosin light chain, alteration in 
tight-junction proteins and an altered cellular distribution of occludin. (111) 
A high-fat diet triggers changes in the gut microbiota, but it is the development of 
inflammation that is associated with the obese phenotype 
By comparing obesity-prone and obesity-resistant mice strains fed the same high-fat 
diet researchers found that diet caused similar changes in gut microbiota composition in 
both groups but only in the obese-prone group were inflammation markers 
increased.(111) 
In another study, female RELM null mice, harboring a genetic resistance to intestinal 
inflammation, were found to be resistant to the obesogenic effects of a high-fat diet. 
Even so, they were susceptible to changes in the gut microbiota similar to wild-type 
mice, proving that diet modifies gut microbiota independently from obesity.(112) 
Yet another study evaluated the impact of a high-fat/high-sugar diet in a murine model. 
The investigators concluded that this diet created a specific inflammatory environment 
in the gut, correlated with intestinal mucosa dysbiosis characterized by an overgrowth 
of pro-inflammatory Proteobacteria such as E. coli, a decrease in protective bacteria, 
and a significantly decreased of SCFA concentrations. They added that mice treated 
with an agonist of GPR43 (a SCFA receptor reduced in dysbiosis) were protected 
against chemical-induced colitis. The depletion of fiber generally associated with the 
western type diet could partially explain the decrease of SCFA concentrations, but 
cannot explain the impact of HF/HS diet on global gut dysfunction by itself. (113) 
A more complex approach on the mechanism 
A more integrated view on the mechanism behind the diet-microbiome-host relationship 
proposes a more complex approach.  A recent review postulated that microbes whose 
competitive advantage is dependent on anaerobic respiration, such as Proteobacteria, 
adopt a pro-inflammatory life history strategy which results in increased nitrate and that 
their competitors promote mucosal homeostasis (which limits nitrate). (62) 
Common pathology-associated microbial species seem to thrive in inflammation. A 
recent study showed that nitrate generated as a by-product of the host inflammatory 
response can be utilized by E.coli. Obligate anaerobic microbes such as those belonging 
to the Firmicutes and Bacteroidetes phyla, compete for nutrients that are available for 
fermentation, originating SCFAs, but cannot utilize non-fermentable nutrients. Reduced 
levels of butyrate, starving the epithelial cells as well as decreasing the number of TReg 
cells, promote inflammation. Unlike obligate anaerobic members of the gut microbiota, 
the facultative anaerobic Enterobacteriaceae can use nitrate, S-oxides and N-oxides as 
terminal electron acceptors for anaerobic respiration. The ability to degrade non-
fermentable substrates likely enables E. coli to bypass its competition, which explains 
the fitness advantage conferred by nitrate respiration in the inflamed gut. (114) 
Another important host factor in this relationship is bile secretion. Bile has potent 
antimicrobial properties that can contribute to the selection or exclusion of many 
potential gut microbiota.(115) 
For instance, Bilophila wadsworthia, a sulphite-reducing human pathobiont, is known to 
flourish in the presence of taurine-conjugated bile acid (a rich source in organic 
sulphur). Researchers found that saturated fats induced a bloom in B. wadsworthia that 
was dependant on a host-derived response by means of increased taurocholic acid 
production. Several intestinal pathogens are not only bile-resistant, but highly favored in 
the presence of bile. (116) 
Cholic acid regulates the composition of gut microbiota in rats, inducing similar 
changes to those induced by high-fat diets. Higher amounts of bile acids are also linked 
to lower fecal concentrations of butyrate. This finding suggests bile acids either select 
against the proliferation of butyrate producing bacteria or inhibit the metabolic 
pathways leading to butyrate synthesis. (117) Western-style diets have reduced intake in 
fermentable polysaccharides and are associated with lower levels of SCFAs. Fat types 
that specifically promote taurocholate may exacerbate the inflammatory processes since 
they are strongly linked to expansion of sulfate-reducing bacteria and production of H2S 
enhances the competitiveness of bacteria that drive systemic inflammation via LPS. 
Dietary intervention acts on the obesity-related microbiota 
Weight loss on two types of low-calorie diet increased the lowered 
Bacteroidetes:Firmicutes proportion found in most obese individuals. (118) In a recent 
study, diet with added fiber also shifted the Bacteroidetes:Firmicutes ratio toward that 
previously associated with healthy lean subjects, and this was independent of caloric 
restriction. Added fiber altered microbial community structure rather than introducing 
or removing existing community members. Shifts in bacterial gene abundances after 
fiber supplementation included genes associated with carbohydrate, amino acid, and 
lipid metabolism, as well as metabolism of cofactors and vitamins. Nonetheless, several 
taxonomic shifts would argue against benefits of fiber, such as reduction of known 
butyrate producers and fecal butyrate concentrations. (119) 
Using microbiota targeting therapies in obesity 
Rebalancing the gut microbiota seems to be a possible manner to intervene in metabolic 
syndrome patients. Most trials that focus on using probiotics to modify human 
metabolism use Lactobacillus and/or Bifidobacterium strains. These are fermentative 
species whose community-level impact on the flora might be limited. Other limitations 
of such trials are small sample sizes and absence of longer-term follow up. Results are 
underwhelming. (120) In theory, as exposed earlier in this review, the ideal age to 
enhance ideal microbiota establishment would be during its development. Even so, only 
two randomized controlled trials regarding early probiotic use for metabolic syndrome 
have been published with no significant long-term results having being detected. (121) 
In 2012 the only study regarding fecal microbiota transplantation and metabolic 
syndrome was published. Eighteen male individuals were screened for metabolic 
syndrome (30 kg/m
2
 or waist circumference > 102 cm and a fasting plasma glucose 
level >5.6 mmol/L), randomized, and allotted in two groups: one receiving an 
autologous transplant and the other a transplant from a lean donor. The results of this 
double-blind controlled trial showed an improvement in insulin sensitivity along with an 
increase in butyrate producing bacteria and increased gut microbiota diversity.(122) 
It seems unlikely that fecal transplantation performed through invasive methods could 
be used routinely for the treatment of obesity, metabolic syndrome or other non-acute 
diseases. As advances in the procedure are pushed forward in clinical research aimed at 
diseases such rCDI, the use of more controlled inoculums as in bacteriotherapy, that is, 
inoculums consisting of selected specific bacterial groups would arise. 
 
 
 
 
 
 
 
Conclusion 
The gut microbiota’s role in human homeostasis is more complex than expected. As the 
knowledge what concerns its functions becomes apparent, the increasing diversity of 
applicabilities becomes tempting. Limitations in current technology such as the inability 
to differentiate between potentially different bacteria belonging to the same phylotype, 
or even less than ideal sampling efforts, might allow a certain distortion of results that 
further research could elucidate. Instead of using bacteria associated with fermentation, 
FMT modifies the recipient’s microbiota using a community of organisms isolated from 
a healthy gut. The knowledge gained from the use of FMT for the treatment of recurrent 
C. difficile infection may pave the way for modern therapies acting on the microbial 
component of many diseases.  
Shaping the adult microbiome has its difficulties due to its inherent stability and 
resistance to change. Acting in a defining timeframe such as the perinatal period might 
be the key for optimal microbiota development.  
It is now evident that diet plays a fundamental role in shaping the gut microbiome. 
Presumed dietary-driven historical microbial extinctions may be responsible for the 
disappearance of symbiotic microbes in modern populations. Also, the high-fat, high-
sugar and low-fiber diet clearly partakes in the lower diversity now commonly observed 
in the industrialized world. The disruption of host-microbiota interaction, termed 
dysbiosis, is linked to several “western” diseases including obesity. Even though a 
causal relationship between microbiota and obesity in humans hasn’t been clearly 
established, evidence for its linkage is increasing. Restoring inaccessible, potentially 
beneficial microbes alongside dietary changes might be the future of personalized 
medicine.  
 
 
 
 
 
 
 
 
 
 
Annex 
Protocol for Fecal Microbiota Transplantation 
Donors (<60 years of age) were volunteers who were initially screened using a 
questionnaire addressing risk factors for potentially transmissible diseases. Donor feces 
were screened for parasites (including Blastocystis hominis and Dientamoeba fragilis), 
C. difficile, and enteropathogenic bacteria. Blood was screened for antibodies to HIV; 
human T-cell lymphotropic virus types 1 and 2; hepatitis A, B, and C; cytomegalovirus; 
Epstein–Barr virus; Treponema pallidum; Strongyloides stercoralis; and Entamoeba 
histolytica. A donor pool was created, and screening was repeated every 4 months. 
Before donation, another questionnaire was used to screen for recent illnesses. Feces 
were collected by the donor on the day of infusion and immediately transported to the 
hospital. Feces were diluted with 500 ml of sterile saline (0.9%). This solution was 
stirred, and the supernatant strained and poured in a sterile bottle. Within 6 hours after 
collection of feces by the donor, the solution was infused through a nasoduodenal tube 
(2 to 3 minutes per 50 ml). The tube was removed 30 minutes after the infusion, and 
patients were monitored for 2 hours. For patients who had been admitted at referring 
hospitals, the donor-feces solution was produced at the study center and immediately 
transported and infused by a study physician. (8) 
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